Thiopurine immunosuppressant-induced pancreatitis

Summary

Thiopurine immunosuppressant-induced pancreatitis (MONDO:0005589) is a disease with 1 GWAS associations across 1 studies. A subtype of pancreatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thiopurine immunosuppressant-induced pancreatitis
Mondo ID	MONDO:0005589
EFO	EFO:0006315
Is cancer (heuristic)	no

Data availability: 1 GWAS association (1 study).

Disease family

This is a subtype of pancreatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › pancreas disorder › pancreatitis › thiopurine immunosuppressant-induced pancreatitis

Related subtypes (4): alcoholic pancreatitis, chronic pancreatitis, acute pancreatitis, autoimmune pancreatitis

Genetics & variants

GWAS landscape

1 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs6935723	1e-21	MTCO3P1 - HLA-DQB3	C	2.46

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST002607	Heap GA	2014	172	2,035	HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs6935723	6	32713892	T>C	0.27	intergenic_variant	MTCO3P1 - HLA-DQB3	1e-21	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.